The global celiac disease diagnostics industry is projected to reach US$ 647.3 million by 2033, growing at a CAGR of 8.3%, the net worth of the market is almost US$ 292.8 million in 2023. The market is driven by increasing awareness of celiac disease, rising prevalence of the disease, and technological advancements in diagnostic tests.
The immune system of the body attacks gluten, a protein present in wheat, rye, and barley, in people with celiac disease. Small intestinal lining damage from this reaction can result in a number of symptoms, such as bloating, diarrhoea, weight loss, and stomach pain. Untreated celiac disease can result in major side effects like malnutrition and a higher chance of developing specific cancers.
Request A Sample Copy of This Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-17187
In persons with celiac disease, the protein gluten, which is found in wheat, barley, and rye, triggers an immune reaction. In this illness, consuming gluten triggers an immunological reaction in the small intestine that manifests as diarrhoea, bloating, vomiting, or abdominal pain.
The celiac disease diagnostics market offers significant opportunities for growth and expansion. The key players in the market are focusing on developing new and innovative diagnostic tests that are more accurate, non-invasive, and affordable. The increasing awareness of celiac disease and the growing demand for gluten-free products are also expected to drive the growth of the market in the coming years.
Key Takeaways:
- North America is expected to remain the largest market for celiac disease diagnostics throughout the forecast period.
- The celiac disease serology tests segment is expected to account for the largest share of the market in 2023, but the molecular diagnostics segment is expected to grow at the fastest CAGR during the forecast period.
- The rising demand for non-invasive and point-of-care diagnostic tests is expected to boost the growth of the celiac disease diagnostics market in the coming years.
Factors driving the growth of the celiac disease diagnostics market:
- Increasing awareness of celiac disease: Celiac disease is a chronic autoimmune disorder that causes damage to the small intestine when gluten is consumed. Gluten is a protein found in wheat, rye, and barley. While celiac disease has been known for centuries, awareness of the disease has increased significantly in recent years. This is due in part to public awareness campaigns by celiac disease organizations as well as the increasing availability of gluten-free foods.
- Rising prevalence of celiac disease: The prevalence of celiac disease is estimated to be around 1% of the global population. However, some studies suggest that the prevalence may be even higher. This is likely due to a number of factors, including genetic predisposition, environmental triggers, and the increased consumption of gluten-containing foods.
- Increasing availability of diagnostic tests: There are a number of diagnostic tests available for celiac disease. The most common test is a blood test that looks for antibodies to gluten. If the blood test is positive, a biopsy of the small intestine may be performed to confirm the diagnosis. In recent years, there has been an increasing development of non-invasive diagnostic tests, such as genetic testing and stool testing. These tests are still under development, but they have the potential to make the diagnosis of celiac disease easier and more accessible.
Reach Out To Our Analyst For Prompt Assistance With Your Questions! https://www.futuremarketinsights.com/ask-question/rep-gb-17187
Key Companies Profiled:
- Thermo Fisher Scientific Inc.
- PRIMA Lab SA
- Glutenostics, Inc.
- NanoRepro AG.
- Targeted Genomics
- YORKTEST Laboratories
- Biohit Oyj
- Labsystems Diagnostics Oy
- RxHome Test
- Biomerica
- AESKU.GROUP GmbH
- LaCAR MDx Technologies
- J. Mitra & Co. Pvt. Ltd.
- Imaware
- Vitrosens Biotechnology
- Bio-Rad Laboratories Inc.
- Eurofins Scientific
Key Segments Covered in Celiac Disease Diagnostics Industry Research:
By Product Type:
- Serology Rapid Testing Kits
- Transglutaminase Antibody Test Kits
- Endomysial Antibody Test Kits
- Anti-Giladin Antibody Test Kits
- Genetic Rapid Testing Kits
By Technique:
- Immunochromatography (Lateral Flow)
- enzyme-linked immunosorbent assay (ELISA)
By Sample:
- Blood Serum
- Body Fluids
By End User:
- Hospitals
- Diagnostic Laboratories
- Specialty Clinics
- Home Care Setting
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Revolutionizing Customer Engagement: Learn from Our Customization Report! https://www.futuremarketinsights.com/customization-available/rep-gb-17187
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
